Lecture Notes - THC and Physical Dependence
Lecture 12: THC and Physical Dependence
Overview
The lecture continues the discussion on THC (Tetrahydrocannabinol), focusing on two main questions:
Does tolerance develop to the effects of THC?
Is physical dependence indicated by withdrawal syndrome associated with THC?
Tolerance to THC
Studies (both animal and human) indicate that tolerance develops to almost all effects of THC.
In humans, tolerance can be observed in self-reported intoxication levels (the "high" effect), often leading individuals to increase their dosages to regain the original effects.
Important points about tolerance:
Requires high blood THC levels and extended periods of use.
Recreational users who utilize THC infrequently are less likely to develop tolerance or physical dependence.
Implications due to increased marijuana legalization:
Higher THC levels in current marijuana strains may lead to increased tolerance and potential physical dependence in users.
Gender Differences in THC Effects
Research indicates that females experience different effects with THC compared to males:
Greater initial sensitivity to THC.
Greater development of tolerance.
More severe withdrawal symptoms indicative of physical dependence.
This observation parallels previous discussions on the gender differences in the effects of alcohol.
Physical Dependence and Withdrawal Symptoms
Previous beliefs: THC was thought not to produce physical dependence. Current understanding is that:
THC does induce physical dependence, evidenced by withdrawal symptoms.
Withdrawal symptoms include:
Mental and physical discomfort upon cessation.
Reasons for previous skepticism regarding THC and dependence:
High dosing required for tolerance, affecting probability of developing physical dependence in typical recreational users.
THC's long elimination half-life (up to 5 days) contributes to less severe withdrawal symptoms. Those undergoing withdrawal are essentially weaning off gradually rather than stopping abruptly.
Lack of a THC antagonist historically made it challenging to assess withdrawal effects accurately. However, a THC antagonist, Rimonabant, now allows for effective testing of physical dependence in research.
Withdrawal Symptoms in Research
Research findings:
Animals (e.g., rats) show withdrawal symptoms resembling those of wet dog shakes and retropulsion.
Monkeys display tremors, aggression, and irritability during withdrawal.
Human studies show similarities in withdrawal symptoms between cannabis and tobacco, confirming the physical dependence of cannabis.
Symptoms associated with tobacco withdrawal that are mirrored in cannabis withdrawal: irritability, insomnia, etc.
Notable exception: Cannabis users tend to experience appetite suppression while tobacco users typically experience an appetite increase during withdrawal.
Duration and Nature of Withdrawal Symptoms
Acute withdrawal symptoms generally subside within 7 to 10 days.
Prolonged effects, termed post-acute withdrawal symptoms (PAWS), can persist for weeks, months, or even years, potentially leading to cravings and relapse.
Treatment of Marijuana Use Disorder (MUD)
Approximately 30% of marijuana users may meet the criteria for MUD at some point in their lives.
Factors influencing the likelihood of developing MUD:
Age of onset: Early use (before age 18) significantly increases the risk (7-fold increase).
Majority of users typically begin before age 18, raising concerns for future dependence.
Treatment-seeking Statistics:
Around 15% of individuals seeking treatment for use disorders report marijuana as their primary substance of concern.
Profile of treatment seekers: predominantly young males, often Caucasian.
Comparison of Addiction Potential with Other Substances
Probability of requiring treatment following recreational use:
Marijuana: ~10%
Alcohol: 15-25%
Cocaine: ~17%
Heroin: ~23%
Tobacco: Highest likelihood
Treatment Approaches for MUD
Treatment modalities for MUD are similar to those used for other substance use disorders (e.g., alcohol, cocaine).
No specific pharmacological treatment currently exists for MUD, unlike treatments available for alcohol use disorder (e.g., Naltrexone, Acamprosate) or for opioid use disorder (e.g., Methadone, Buprenorphine).
Treatment outcomes suggest similar effectiveness across different substances, implying common underlying causes for substance use disorders regardless of the specific drug used.
Synthetic Cannabinoids
Naturally occurring THC-like substance: Anandamide.
Development of synthetic cannabinoids aimed to enhance effectiveness or minimize side effects.
First synthetic cannabinoid developed by John Huffman (no need to remember the name).
Key Characteristics of Synthetic Cannabinoids:
Known as new psychoactive substances, often referred to as "Spice."
Produced in illegal labs leading to unpredictable and potent THC-like effects, including severe adverse reactions (e.g., seizures).
Estimated 30,000 emergency room visits annually linked to synthetic cannabinoid use.
Comparison of THC potency:
Naturally occurring THC's dose for specific effects vs. synthetic cannabinoids requiring significantly lower doses to achieve similar effects, showing their increased potency.
Conclusion
The discussion wraps up the effects and implications surrounding THC and leads into the next lecture covering tobacco use.